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Abstract 
Purpose: To determine the effect of quercetin on bupivacaine-induced neurotoxicity and to investigate 
the mechanisms involved. 
Methods: Cultured SH-SY5Y cells were divided into five treatment groups: control group with no drug, 
bupivacaine treatment group, quercetin group, bupivacaine--quercetin combination treatment group, 
and bupivacaine-mibefradil combination treatment group. Cell morphology in each group was examined 
by microscopy while cell viability was assessed by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-
tetrazolium bromide (MTT) assay after 24 h incubation. Cytosolic calcium ion concentration was 
determined by flow cytometry while Cav3.1 protein expression was evaluated by western blot.  
Results: Quercetin (50 µM) significantly (p < 0.05) protected SH-SYS5 cells from bupivacaine-induced 
cell apoptosis and also significantly reduced intracellular calcium ion concentration (p < 0.01) by 
approximately 40 %. Cav3.1 protein expression was normalized following quercetin treatment. 
Conclusion: These results show that quercetin reduces the neurotoxicity induced by bupivacaine, 
possibly through inhibition of T-type calcium channel. This finding implies a novel mechanism for neuro-
protective effect of quercetin, and its potential for treating toxicity arising from the use of local anesthetic 
agents. 
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Local anesthetic agents are widely used in 
hospitals; however they are also associated with 
certain side effects, especially neurotoxicity. It 
has been shown that neurotoxicity caused by 
local anesthetics such as lidocaine and 
bupivacaine are related to changes in calcium 
homeostasis, resulting in intracellular calcium 
overload [1]. Calcium homeostasis is regulated 
by many different kinds of calcium channels such 
as the ligand-gated calcium channels and 
voltage-gated calcium channels (VGCCs) [2]. 
VGCCs are categorized into two types: high 
voltage-activated calcium channels (e.g. L and 
N-type calcium channel), and low voltage-
activated calcium channels (T-type calcium 
channel; T represents transient) [3]. Recent 
studies indicated that blocking T-type calcium 
channels or inhibiting its activation protected 
neurons against apoptosis under severe 
conditions [4]. 
  
Quercetin (chemical structure given in Figure 1) 
is a bioflavonoid widely found in many fruits and 
leaves, and it has been used as health 
supplement claimed to prevent or treat a variety 
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of diseases, although there are no clinical data to 
back these claims [5]. However, extensive cell 
and animal-based studies have demonstrated its 
many efficacies including anti-oxidative, anti-
inflammatory and anti-tumor properties [6, 7].  
 
The current study is focused on the protective 
effect of quercetin on neurons against 
bupivacaine-induced neurotoxicity. The effect of 
quercetin on the expression of T-type calcium 
channels was also evaluated to investigate the 






The cell line (SH-SY5Y) was bought from 
Shanghai Institute for Biological Sciences 
(Shanghai, China). Mibefradil dihydrochloride, 
bupivacaine hydrochloride, quercetin and MTT 
were products of Sigma (St. Louis, MO, USA). 
Anti-Cav3.1 mono-clonal antibody, anti-β-actin 
mono-clonal antibody and horseradish 
peroxidase-conjugated polyclonal antibody were 
purchased from Santa Cruz (Santa Cruz, CA, 
USA). DMEM/F12 medium and fetal bovine 
serum (FBS) was from Gibco (Grand Island, NY, 
USA). Fluo-8® AM ester was bought from AAT 
Bioquest Inc. (Sunnyvale, CA, USA). All other 
reagents purchased from commercial vendors 
were of analytical grade. 
 
Cell culture, cell morphology and cell viability 
assay  
 
SH-SY5Y cells were cultured in DMEM/F12 
medium with 10 % FBS, (with 150 μg/mL 
streptomycin and 150 units/mL penicillin) at 37 
°C in a humidified CO2 incubator. The medium 
was replaced every other day. To examine the 
effect of quercetin on bupivacaine-induced 
neurotoxicity, cultured SH-SY5Y cells were 
divided into five groups: control group (C), 
bupivacaine (1 mM) group (B), quercetin (50 μM) 
group (Q), quercetin (50 μM) with bupivacaine (1 
mM) group (Q+B, and mibefradil (10 μM) with 
bupivacaine (1 mM) group (M+B). In the 
quercetin (50 μM) with bupivacaine (1 mM) group 
and the mibefradil (10 μM) with bupivacaine (1 
mM) group (M+B), 50 μM of quercetin or 10 μM 
mibefradil was added to cell culture media 2 h 
prior to bupivacaine (1 mM) exposure. After 24 h 
incubation, the cells in the wells in each 
treatment group were placed under a microscope 
(IX73, Olympus) for cell morphology observation. 
The cell images were captured by digital camera 
at 100x magnification. 
 
Cell viability in each treatment group was 
determined by MTT viability assay. Generally, 
the cells were seeded into 96-well plates (four 
thousand cells per well) with 200 µL culture 
media per well, and incubated overnight before 
drug treatment. On the next day, the culture 
medium was changed with 200 µL fresh media 
containing appropriate drug(s). The cells were 
incubated for another 24 h before MTT addition 
(20 μL). After 4 h, the absorbance of each well in 
the 96-well plate was measured at 570 nm in a 
microplate reader (Fisher Scientific, Waltham, 
MA, USA). The mean absorbance of the control, 
untreated group was set as 100 % cell survival 
and the cell viability in every other treatment 
group was calculated relative to the control. 
 
Determination of intracellular calcium ion 
concentration 
 
Intracellular calcium ion concentration was 
analyzed using commercially available Fluo-8® 
AM ester probe in accordance with the product 
instruction manual. Fluo-8® AM ester stock 
solution (5 mM) was first dissolved in anhydrous 
dimethyl sulphoxide (DMSO). A testing solution 
(10 μM) was then prepared with the cell culture 
media (without FBS) containing 0.02 % 
Pluronic® F-127. Each 200 μL of testing solution 
was added to the culture media in the plates with 
live cells (final probe concentration was kept at 5 
μM). After 20 min incubation at 25 oC, the live 
cells were washed several times with HEPES 




Figure 1: Chemical structures of quercetin and mibefradil 
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The live cells were then analyzed by flow 
cytometry (BD FACSCelestaTM, BD Biosciences, 
San Jose, CA, USA) at an excitation and 
emission wavelength of 490 and 525 nm, 
respectively. The following equation was used to 
calculate the intracellular calcium ion 
concentration (Eq 1). 
 
[Ca2+] = Kd*(F-Fmin)/(Fmax-F) …………… (1) 
 
where F represented the fluorescence intensity 
of the probe in each experimental group; Fmin 
represented the fluorescence intensity without 
calcium ion; and Fmax represented the 
fluorescence intensity of the calcium ion-
saturated probe. The dissociation constant (Kd), 
reflecting the affinity of the probe for calcium, 
was set at the theoretical value (389 nM) as 
provided in the manual.  
 
Determination of Cav3.1 protein expression 
by western blotting 
 
Total protein from cells in each treatment groups 
was extracted to determine Cav3.1 protein 
expression. The sample cells were lysed and the 
total protein concentration in the supernatant was 
determined by the BCA protein assay kit (Fisher 
Scientific, Waltham, MA, USA). 20 μg of protein 
from each sample was separated by 12 % SDS-
PAGE before transferring to polyvinylidene 
difluoride (PVDF) membrane for western blotting. 
The membranes were then blocked with 5 % milk 
(fat-free) in Tris buffered saline (containing 0.05 
% polysorbate 20) for 1 h at 25 oC, and then 
incubated with primary antibodies that were 
against Cav3.1 (1: 500) or β-actin (1: 500) 
overnight under gentle agitation at 4 oC.  
 
Thereafter, the membranes were incubated with 
secondary antibody (horseradish peroxidase-
conjugated IgG, 1:1000) for another 1½ h at 25 
oC. The membranes were washed three times 
with Tris buffered saline, after which they were 
developed by enhanced chemiluminescence 
(ECL, Thermo Scientific, Shanghai, China) 
followed by exposure to X-ray films. The films 





All data are expressed as mean ± standard 
deviation (SD), and were analyzed using SPSS 
18.0 software. One-way ANOVA test with Tukey 
post-test was performed for multiple 






Effect of quercetin on cell morphology 
 
No substantial morphological difference was 
found in the SH-SY5Y cells treated with 
quercetin when compared with the control group 
(Figure 2). However, after exposure to 
bupivacaine (1 mM) for 24 h, most cells became 
abnormal: they were inflated and more rounded 
in shape; detached and floating cells were easily 
observed. A small percentage of cells in the 
quercetin-bupivacaine co-treatment group, as 
well as a fraction of cells in the mibefradil-
bupivacaine co-treatment group also showed 
abnormal cell morphology as the cells in 
bupivacaine-only group. However, the majority of 
the cells in the two co-treatment groups 





There were no significant differences in the cell 
viabilities between the control group after 24 h 
(C-24) and quercetin-treated group after 24 h (Q-
24) (113.2 ± 19.7 % and 103.6 ± 16.8 %, 
respectively, Figure 3). The cell viabilities in the 
bupivacaine-only group (B-24), the quercetin-
bupivacaine co-treatment group (Q+B-24) and 
the mibefradil-bupivacaine co-treatment group 
(M+B-24) after 24 h were 31.3 ± 3.5 %, 61.7 ± 
2.9 % and 61.8 ± 8.7 %, respectively. The cell 
viabilities in B-24, Q+B-24 and M+B-24 groups 
were significantly decreased when compared to 
the control (p < 0.05; Figure 3). However, the cell 
viabilities in the quercetin-bupivacaine co-
treatment group (Q+B-24) and cell viability in the 
mibefradil-bupivacaine co-treatment group (M+B-
24) were significantly higher than that in the 
bupivacaine-only group (B-24) (p <0.05; Figure 
3). Both quercetin and mibefradil protected the 
SH-SY5Ycells against bupivacaine-induced 
toxicity, leading to increased cell viability. 
 
Intracellular calcium ion concentrations 
 
There were no statistically significant differences 
in intracellular calcium ion concentrations 
between the control group and the quercetin-only 
treatment group (C-24 and Q-24) (407 ± 31 nM 
and 416 ± 18 nM, respectively). However, 
calcium ion concentration in the 1 mM 
bupivacaine treatment group (B-24, 817 ± 65 nM) 
was significantly (p <0.01) higher than that in the 
control group. Both quercetin and mibefradil 
treatments caused significant reduction by nearly 
40 % (p <0.01) of the intracellular calcium ion 
concentration in cells exposed to bupivacaine. 
The cytosolic calcium ion concentrations were 
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505 ± 36 nM and 485 ± 45 nM in Q+B-24 and 
M+B-24 groups, respectively (Figure 4A and 
Figure 4B). 
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and 416 ± 18 nM, respectively). However, 
calcium ion concentration in the 1 mM 
bupivacaine treatment group (B-24, 817 ± 65 nM) 
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Figure 2: Representative cell morphologies in the different treatment groups after 24 h. The cells 
were imaged under microscopy. Most cells in B-24 showed abnormal morphologies (arrow showed 
representative round and inflated cells) when compared to those in the control group, while cells in 
Q+B-24 and M+B-24 showed both normal and abnormal morphologies, even though the abnormal 
cells were only a small part. 
 
 
Figure 3: Cell viabilities in different treatment groups after 24 h. The cell viability was determined by 
MTT assay. Cell viability was lowest in B-24 group, followed by Q+B-24 and M+B-24 groups. Data is 
expressed as mean ± SD. One-way ANOVA was used as statistical method. * p < 0.05: B-24 versus 
Q+B-24/M+B-24; ** p <0.01: C-24 versus B-24/ Q+B-24/M+B-24 
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Figure 4: Intracellular calcium ion concentrations in 
different groups at 24 h. (A) Representative flow 
cytometry analysis results in each group; (B) the 
calculated intracellular calcium ion concentrations in 
each group. Data are expressed as mean ± SD. A 
one-way ANOVA was used as statistical method; **p < 




It was found that T-type calcium channels might 
be involved in neuronal apoptosis caused by 
local   anesthetic   related   toxicity   and   certain  
 
 
Figure 5: Cav3.1 protein expressions in each 
treatment group. Cav3.1 expression was detected by 
western blot; β-actin served as the control; Cav3.1 
expression was highest in B-24, followed by Q+B-24 
and M+B-24, and was lowest in C-24 and Q-24 
 
specific T-type calcium channel blocker such as 
NNC 55-0396 dihydrochloride could suppress the 
toxicity [8,9]. The present study demonstrated 
that an herbal medicine called quercetin, at 50 
μM concentration, protected SH-SY5Y cells from 
bupivacaine-induced cellular death, and was as 
effective as mibefradil, one T-type calcium 
channel blocker, at 10 μM concentration. The 
neuro-protective effects of T-type calcium 
channel blockers (such as mibefradil) have been 
reported before [10]. For example, Bancila et al. 
found that mibefradil administration prevented 
neuronal death after ischemia in a global 
ischemia rat model [11]. The results obtained in 
the present study show the neuro-protective 
effect of mibefradil against bupivacaine-induced 
neurotoxicity and revealed that quercetin could 
also alleviate bupivacaine-induced cell damage, 
although at a relatively high concentration. It was 
also found that quercetin at 10 μM did not 
improve the cell viability (data not shown) after 
bupivacaine exposure, suggesting that the 
protective effect of quercetin was likely 
concentration-dependent.      
 
Wen et al found that the expression of Cav3.1 
(the main sub-unit of T-type calcium channel) 
was up-regulated by lidocaine [8]. The elevated 
calcium channel expression mediates calcium 
ion influx, resulting in increased intracellular 
calcium ion concentration. This would trigger the 
phenomena called calcium-induced calcium 
release, giving rise to more calcium release from 
cellular calcium storage organelle - the 
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endoplasmic reticulum. The resultant intracellular 
calcium overload leads ultimately to cell 
apoptosis [8]. In the present study, 1 mM 
bupivacaine treatment effectively activated 
Cav3.1 expression and significantly increased 
intracellular calcium ion concentration. This is 
consistent with findings in earlier reports. 
However, it was found that quercetin at 50 μM, 
equivalent to mibefradil at 10 μM, substantially 
reduced Cav3.1 expression and resulted in 
marked decrease in cytosolic calcium ion 
concentration in cells exposed to bupivacaine. 
The calcium ion concentration in cells from either 
the quercetin or mibefradil treatment group was 
almost at par with that in the control group level.  
 
The in vitro and in vivo applications of quercetin, 
an anti-oxidant flavonoid have been extensively 
investigated. Quercetin has been shown to exert 
protective effects against cardiovascular 
diseases like atherosclerosis and ischemia re-
perfusion-induced injury, as well as anti-cancer 
and anti-inflammatory effects [12]. Recent 
studies have also revealed the neuro-protective 
effects of quercetin in many neurodegenerative 
diseases such as Alzheimer’s disease and 
Parkinson’s disease, and against hypoxia-
induced injury and neurotoxic chemical-induced 
damage [13,14]. However, the mechanisms 
underlying these effects were not fully 
understood. It was previously suggested that 
quercetin exerted neuro-protective effects and 
cellular defenses against oxidative stress via the 
induction of Nrf2-ARE (nuclear factor erythroid 2-
related factor 2-antioxidant response element) 
and the anti-oxidant enzyme paraoxonase 2 
(PON2) [13].  
 
In the present study, the reduced intracellular 
calcium ion concentration and decreased Cav3.1 
protein expression in quercetin-bupivacaine co-
treatment group suggest the likely involvement of 
the inhibition of T-type calcium channels by 
quercetin in the neuro-protective effect of 




There were some limitations in this study. In the 
first place, the study was conducted on SH-
SY5Y, the transformed neuroblastoma cells in 
vitro. The results obtained may not readily be 
applicable to neurons in vivo. Secondly, as an 
anti-oxidant, quercetin could also influence many 
other molecular targets and pathways such as 
ROS generation. It has been reported that 
another anti-oxidant, ginkgolide B effectively 
protected SH-SY5Y from bupivacaine caused 
apoptosis mainly through suppression of ROS 
accumulation [15]. The impact of quercetin’s free 
radical scavenging property can hardly be 
excluded [16]. These limitations notwithstanding, 
the neuro-protective effect of quercetin was well-




The findings of this study show that quercetin 
significantly reduces bupivacaine-induced 
neurotoxicity possibly by inhibition of T-type 
calcium channels. Although the detailed 
molecular mechanism needs to be further 
investigated, the present findings indicate the 
potential application of quercetin in the treatment 
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